Authors
Mikael Erhardsson, Lars Lund, Lina Benson, Gianluigi Savarese, Giulia Ferrannini, Ulrika Ljung Faxén, Ulf Dahlström, Camilla Hage
Published in
Heart (British Cardiac Society). Aug 25, 2026. Epub Aug 25, 2026.
Abstract
Effective decongestion is a key therapeutic goal during hospitalisation for acute heart failure (HF), but the clinical significance of intravenous loop diuretic-induced weight loss and its relationship with biomarker changes remain uncertain.
We included patients hospitalised for HF in the nationwide Swedish Heart Failure Registry (2017-2021) who received intravenous loop diuretics, survived to discharge and had body weight recorded at admission and discharge. Weight loss was defined as ≥2 kg between admission and discharge. Associations between weight loss, changes in biomarkers (estimated glomerular filtration rate (eGFR), N-terminal pro-B-type natriuretic peptides (NT-proBNP), haemoglobin, sodium and potassium) and outcomes were evaluated. The primary outcome was rehospitalisation for HF (re-HHF); the secondary outcome was the composite of cardiovascular death or re-HHF at 30 days and 1 year.
Among 4979 patients (median age 80 years; 57% male), median weight change during hospitalisation was -2.5 kg and 2949 (59%) achieved weight loss ≥2 kg. Male sex, atrial fibrillation, obesity, higher admission NT-proBNP and mineralocorticoid receptor antagonist use were independently associated with weight loss. Weight change showed no meaningful association with change in eGFR. Weight loss was independently associated with a lower risk of re-HHF (HR 0.59, 95% CI 0.53 to 0.67) and the composite of cardiovascular death or re-HHF (HR 0.76, 95% CI 0.69 to 0.84) within 30 days but not thereafter. These associations were consistent irrespective of biomarker changes, including worsening renal function.
In this nationwide cohort of patients hospitalised for HF and treated with intravenous loop diuretics, diuretic-induced weight loss, a pragmatic marker of decongestion, was associated with improved short-term clinical outcomes without an accompanying decline in renal function and irrespective of biomarker changes, including worsening renal function.
PMID:
42642074
Bibliographic data and abstract were imported from PubMed on 26 Aug 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 16
- Comments 0